血必净注射液联合抗血小板治疗急性冠脉综合征的临床研究

Clinical Study on Xuebijing Injection Combined With Antiplatelet Therapy for the Treatment of Acute Coronary Syndrome

目的 研究血必净注射液联合抗血小板治疗急性冠脉综合征的临床治疗效果。方法 将2014年7月~2016年1月于我院接受治疗的84例急性冠脉综合征患者根据治疗方式不同,分为对照组和治疗组。对照组在常规治疗的基础上给予抗血小板治疗（阿司匹林联合氯吡格雷）,治疗组在对照组治疗基础上给予血必净注射液治疗,观察两组治疗前后血小板凝集率、血清超敏C-反应蛋白以及治疗效果。结果 两组患者治疗后PAR和hs-CRP均显著低于治疗前,差异具有统计学意义（P〈0.05）;并且治疗后治疗组下降幅度高于对照组（P〈0.05）;对照组患者显效17例,有效14例,无效11例,总有效率73.81%,而治疗组则分别为28例,12例,2例,总有效率95.24%,显著高于对照组,差异具有统计学意义（P〈0.05）。结论 血必净注射液联合抗血小板治疗急性冠脉综合征,可显著降低患者血小板凝集,降低体内炎症反应,治疗效果好,是治疗ACS有效药物。

Objective To study the clinical effect of Xuebijing injection combined with antiplatelet therapy in the treatment of acute coronary syndrome.Methods 84 cases of patients with acute coronary syndrome treated in our hospital from July 2014 to January 2016 were randomized into control group and treatment group according to the different treatment methods. Based on conventional treatment, the control group was treated with antiplatelet therapy （aspirin combined with clopidogrel）. On the basis of the control group, the treatment group was treated with Xuebijing injection. Platelet aggregation rate, serum high-sensitivity C- reactive protein and therapeutic effect in the two groups were observed before and after treatment.ResultsAfter treatment, PAR and hs-CRP in the two groups were significantly lower than those before treatment, the difference was statistically significant （P〈0.05）, and the decreasing range in treatment group was significantly greater than that in control group, the difference was statistically signiifcant （P〈0.05）; In the control group, there were 17 markedly effective cases, 14 effective cases and 11 ineffective cases, and the total effective rate was 73.81%, while in the treatment group, there were 28 cases, 12 cases and 2 cases, respectively. The total effective rate （95.24%） was signiifcantly higher than that in the control group, the difference was statistically signiifcant （P〈0.05）.Conclusion The application of Xuebijing injection combined with antiplatelet therapy in the treatment of acute coronary syndrome can signiifcantly reduce platelet aggregation and reduce the inlfammatory reactions. The treatment effect is good. It is an effective drug for the treatment of ACS.